DOI: https://doi.org/10.24959/sphhcj.19.163

The market review of drugs for the prevention and treatment of urogenital symptoms in the pre- and postmenopausal period

O. I. Ivanyuk, T. G. Yarnikh, O. M. Ievtushenko

Abstract


In 60-80 % of premenopausal or postmenopausal women various clinical manifestations of the estrogen-deficiency state may appear, i.e. climacteric disorders. The structure of the domestic market of drugs used in these cases is quite extensive and includes both hormonal and non-hormonal medicines, homeopathic, medicinal plant raw material, and others.

Aim. To review the market of drugs for the prevention and treatment of urogenital symptoms in the pre- and postmenopausal period in order to identify marketing opportunities for domestic pharmacy.

Materials and methods. The study was conducted using the structural analysis, logical and graphical methods, and marketing analysis methods.

Results. The dynamics of changes and trends in the development of the Ukrainian market for medicinal products of groups of bio-identical estrogens (preparations of G03C A03 estradiol valerite, G03C A07 estron, G03C A04 estriol, G01CA57 conjugated estrogens), G01A X14 enzymes of lactic acid bacteria, progestagens (G03D B01 Dihydroxederosone, G03D A04 Progesterone G03D A02 Medroxyprogesterone acetate, G03F A01 Norethisterone, G03A D01 Levonorgestrel), combined drugs (a combination of estrogen components with progestogen), steroids and combinations of herbal products have been determined. The structure of the market by the number of names, forms of release, manufacturer countries, and the composition has been studied. By the structure of the manufacturer countries the market of these groups of medicines is import-dependent: the share of the Ukrainian drugs in any group does not exceed 12 %. The market of non-hormonal drugs used in the treatment and prevention of urogenital malformations in the menopause has been also described. It is constantly replenished with drugs of the local action (which belong to the groups Medical products 22 and Cosmetics 06). Active substances of plant origin, as well as hyaluronic, lactic, ascorbic acids, vitamins are the most common in their composition. The market is also import-dependent; drugs belong to the high cost category.

Conclusions. Based on the changes identified definite proposals have been developed for the domestic pharmaceutical industry − the market has a very small range of domestic medicinal products that can be used for the treatment and prevention of urogenital disorders in the menopause. For producers they are interesting due to the possibility of using the domestic raw material base, as well as the fact that this group of drugs is included in the high cost niche. Based on the lower cost a domestic manufacturer will be able to offer the market a competitive price, make drugs more affordable, without losing the necessary profitability.

Keywords


pharmaceutical market; medicines; menopause; urogenital symptoms; marketing research

References


Rogovskaia, S. I., Semenova, E. N. (2016). Slovo pro zdorov’ia, 4. Available at: https://ozdorovie.com.ua/novyie-podhodyi-k-probleme-suhosti-vlagalishha-u-zhenshhin/

Zalizniak, V.O. (2016). Suchasni pohliady na zamisnu hormonalnu terapiiu v pery- ta postmenopauzi. Zaporizhzhia: ZDMU, 82.

Yermakova, E. I., Balan, V. E., Tikhomirova, E. V., Lazareva, I. N., Lapina, A. V., Panina, E. M. (2017). Rossiiskii vestnik akushera-ginekologa, 6, 89-95. doi: 10.17116/rosakush201717689-95.

Mnushko, Z. N., Pestun, I. V. (2008). Teoriia i praktika marketingovykh issledovanii v farmatsii.Kharkov: Izdatelstvo NFaU, 308.

Balan, V. E., Kovaleva, L. A., Tikhomirova, E. V. (2016). Meditsinskii sovet, 12, 98-101. doi: 10.21518/2079-701X-2016-12-98-101.

Zaichenko, H. V., Horchakova, N. O., Stryha, O. A., Yakovleva, N. Yu., Ruban, O. I. (2017). Visnyk problem biolohii i medytsyny, 1 (135), 33-42.

Stroitelev, V. (1997). Vestn. novykh med. tekhnol., 3, 98–104.

Baza danykh “Morion”. Available at: https://pharmbase.com.ua/ru/optovye-predlozheniya/ − dated 20.09.2016.

Derzhavnyi reiestr likarskykh zasobiv Ukrainy. Available at: http://www.drlz.com.ua/.

Kompendium: lekarstvennye preparaty. Available at: http://compendium.com.ua/.

Brif-analiz farmrynka: itogi noiabria 2016. (2016). Ezhenedelnik “Apteka”, 1067 (46). Available at: http://www.apteka.ua/article/397246].

Al-Baghdadi, O. (2009). Topical estrogen therapy in the management postmenopausal vaginal atrophy: an up-to-date overview. Climacteric, 12 (2), 91–105. doi: 10.1080/13697130802585576.

Sinha, A., Ewies, A. A. (2013). Non-hormonal topical treatment of vulvovaginal atrophy: an up-to-date overview. Climacteric, 16, 305-312. doi: 10.3109/13697137.2012.756466.

Griebling, T. L., Liao Z., Smith P. G. (2012). Systemic and topical hormone therapies reduce vaginal innervation density in postmenopausal women. Menopause, 19, 630-635. doi: 10.1097/gme.0b013e31823b8983.

Frank, S. M., Ziegler, C., Kokot-Kierepa, M., Maamari, R., Nappi, R. E. (2013). Vaginal Health: Insights, Views & Attitudes (VIVA) survey — Canadian cohort. Menopause Int., 19 (1), 20-27. doi: 10.1258/mi.2012.012034

Pastore, L. M., Carter R. A., Hulka B. S., Wells, E. (2004). Self-reported urogenital symptoms in postmenopausal women: Women’s Health Initiative. Maturitas, 49, 292-303. doi: 10.1016/j.maturitas.2004.06.019.

Stuenkel, C. A., Davis, S. R., Gompel, M. A., Pinkerton, J. V., Santen, R. J. (2015). Menedzhment klimakteriiu, 6 (26). http://press.endocrine.org/суткиoi/abs/10.1210/jc.2015-2236?journalCode=jcem

Baber, R. J., Panay, N., Fenton, A. (2016). 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric, 19.2, 109–150. doi: 10.3109/13697137.2015.1129166.

Santoro, N., Epperson, C. N., Mathews, S. B. (2015). Menopausal symptoms and their management. Endocrinol Metab Clin N Am., 44 (3), 497–515. doi: 10.1016/j.ecl.2015.05.001.

Thompson, J., Ritenbaugh, C., Nichter, M. (2017). Why women choose compounded bioidentical hormone therapy: lessons from a qualitative study of menopausal decision-making. BMC Womens Health, 17, 97. doi: 10.1186/s12905-017-0449-0.


GOST Style Citations


1.  Роговская, С. И. Новые подходы к проблеме сухости влагалища у женщин / С. И. Роговская, Е. Н. Семенова // Слово про здоров’я. – 2016. – № 4. – Режим доступу: https://ozdorovie.com.ua/novyie-podhodyi-k-probleme-suhosti-vlagalishha-u-zhenshhin/

 

2.  Залізняк, В. О. Сучасні погляди на замісну гормональну терапію в пери- та постменопаузі : навч. посібник для самостійної роботи студентів V-VI курсів мед. ф-ту та лікарів-інтернів акушерів- гінекологів / В. О. Залізняк. – Запоріжжя : ЗДМУ, 2016. – 82 с.

 

3.  Генитоуринарный менопаузальный синдром: диагностика и принципы лечения (краткие клинические рекомендации) / Е. И. Ермакова, В. Е. Балан, Е. В. Тихомирова, И. Н. Лазарева, А. В. Лапина, Е. М. Панина // Российский вестник акушера-гинеколога. – 2017. – № 6. – С. 89-95. doi: 10.17116/rosakush201717689-95.

 

4.  Мнушко, З. Н. Теория и практика маркетинговых исследований в фармации: монография / З. Н. Мнушко, И. В. Пестун. − Х. : Изд-во НФаУ, 2008. − 308 c.

 

5.  Балан, В. Е. Генитоуринарный или урогенитальный синдром / В. Е. Балан, Л. А. Ковалева, Е. В. Тихомирова // Медицинский совет. – 2016. – № 12. – 98-101. doi: 10.21518/2079-701X-2016-12-98-101.

 

6.  Аспекти фармакодинаміки та клінічної фармакології гіалуронової кислоти / Г. В. Зайченко, Н. О. Горчакова, О. А. Стрига, Н. Ю. Яковлева, О. І. Рубан // Вісник проблем біології і медицини. – 2017. – Вип. 1 (135). – С. 33-42.

 

7.  Строителев, В. Гиалуроновая кислота – биологически активное вещество, обладающее защитными и иммуномодулирующими свойствами / В. Строителев // Вестн. новых мед. технол. – 1997. – № 3. – С. 98–104.

 

8.  База даних «Моріон» [Електронний ресурс]. – Режим доступу: https://pharmbase.com.ua/ru/optovye-predlozheniya/

 

9.  Державний реєстр лікарських засобів України [Електронний ресурс]. – Режим доступу: http:// www.drlz.com.ua/

 

10.  Компендиум: лекарственные препараты [Електронний ресурс]. – Режим доступу: http:// compendium.com.ua/

 

11.  Бриф-анализ фармрынка: итоги ноября 2016 [Електронний ресурс] // Еженедельник «Аптека». – 2016. – № 1067 (46). – Режим доступу: http://www.apteka.ua/article/397246

 

12.  Al-Baghdadi, O. Topical estrogen therapy in the management postmenopausal vaginal atrophy: an up-to-date overview / O. Al-Baghdadi // Climacteric. – 2009. – Vol. 12, № 2. – P. 91–105. doi: 10.1080/13697130802585576.

 

13. Sinha, A. Non-hormonal topical treatment of vulvovaginal atrophy: an up-to-date overview / A. Sinha, A. A. Ewies // Climacteric. – 2013. – № 16. – P. 305-312. doi: 10.3109/13697137.2012.756466.

 

14.  Griebling, T. L. Systemic and topical hormone therapies reduce vaginal innervation density in postmenopausal women / T. L. Griebling, Z. Liao, P. G. Smith // Menopause. – 2012. – № 19. – P. 630-635. doi: 10.1097/gme.0b013e31823b8983.

 

15.  Vaginal Health: Insights, Views & Attitudes (VIVA) survey — Canadian cohort / S. M. Frank, C. Ziegler, M. Kokot-Kierepa, R. Maamari, R. E. Nappi // Menopause Int. – 2013. – № 19 (1). – P. 20-27. doi: 10.1258/mi.2012.012034.

 

16. Self-reported urogenital symptoms in postmenopausal women: Women’s Health Initiative / L. M. Pastore, R. A. Carter, B. S. Hulka, E. Wells // Maturitas. – 2004. – № 49. – P. 292-303. doi: 10.1016/j.maturitas.2004.06.019.

 

17.  Лечение симптомов менопаузы. Клиническое практическое руководство эндокринологического общества США, 2015 / C. A. Stuenkel, S. R. Davis, M. A. Gompel, J. V. Pinkerton, R. J. Santen // Менеджмент клімактерію. – 2015. – № 6 (26). – Режим доступу: http://press.endocrine.org/суткиoi/abs/10.1210/jc.2015-2236?journalCode=jcem.

 

18.  Baber, R. J. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy / R. J. Baber, N. Panay, A. Fenton // Climacteric. – 2016. – № 19.2. – P. 109–150. doi: 10.3109/13697137.2015.1129166.

 

19.  Santoro, N. Menopausal symptoms and their management / N. Santoro, C.N. Epperson, S. B. Mathews // Endocrinol. Metab. Clin N Am. – 2015. – № 44 (3). –P. 497–515. doi: 10.1016/j.ecl.2015.05.001.

 

20.  Thompson, J. Why women choose compounded bioidentical hormone therapy: lessons from a qualitative study of menopausal decision-making / J. Thompson, C. Ritenbaugh, M. Nichter // BMC Womens Health. – 2017. – № 17. – P. 97. doi: 10.1186/s12905-017-0449-0.





Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Abbreviated key title: Soc. pharm. health care

ISSN 2518-1564 (Online), ISSN 2413-6085 (Print)